132 related articles for article (PubMed ID: 22260811)
21. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
22. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
23. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
[TBL] [Abstract][Full Text] [Related]
24. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
Kristensen LE; Lie E; Jacobsson LT; Christensen R; Mease PJ; Bliddal H; Geborek P
J Rheumatol; 2016 Jan; 43(1):81-7. PubMed ID: 26628604
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
Mori Y; Kuwahara Y; Chiba S; Itoi E
Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
[TBL] [Abstract][Full Text] [Related]
28. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
Holman AJ; Ng E
Auton Neurosci; 2008 Dec; 143(1-2):58-67. PubMed ID: 18632310
[TBL] [Abstract][Full Text] [Related]
29. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.
Ramonda R; Puato M; Punzi L; Rattazzi M; Zanon M; Balbi G; Ortolan A; Frallonardo P; Faggin E; Plebani M; Zaninotto M; Lorenzin M; Pauletto P; Doria A
Joint Bone Spine; 2014 Oct; 81(5):421-5. PubMed ID: 24703399
[TBL] [Abstract][Full Text] [Related]
30. Development of a preliminary US power Doppler composite score for monitoring treatment in PsA.
Gutierrez M; Di Geso L; Salaffi F; Bertolazzi C; Tardella M; Filosa G; Filippucci E; Grassi W
Rheumatology (Oxford); 2012 Jul; 51(7):1261-8. PubMed ID: 22378715
[TBL] [Abstract][Full Text] [Related]
31. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
32. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
33. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
[TBL] [Abstract][Full Text] [Related]
34. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.
Perrotta FM; Lubrano E
Postgrad Med; 2016 Sep; 128(7):693-6. PubMed ID: 27494077
[TBL] [Abstract][Full Text] [Related]
36. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors.
Ballanti E; Perricone C; di Muzio G; Kroegler B; Chimenti MS; Graceffa D; Perricone R
Autoimmun Rev; 2011 Aug; 10(10):617-23. PubMed ID: 21549221
[TBL] [Abstract][Full Text] [Related]
37. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
38. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
39. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
40. Elevated C-Reactive Protein Level Predicts Earlier Treatment with Tumor Necrosis Factor-Alpha Inhibitors in Psoriatic Arthritis.
Ofer-Shiber S; Molad Y
Isr Med Assoc J; 2016 May; 18(5):279-82. PubMed ID: 27430084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
